We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mr
Francis
Dowling
-
francis.dowling@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Antibody-associated psychosis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Psychosis is a mental health condition that causes people to see reality differently, causing hallucinations or delusions. There is some evidence that, rarely, psychosis may be caused by a particular kind of antibody in the blood that affects the brain. Antibodies are molecules which the body makes to fight infections. There is some evidence that getting rid of these antibodies may improve the symptoms of psychosis. Immunotherapy could be helpful for patients with psychosis. Immunotherapy is a type of treatment that aims to boost the body’s natural defences to fight cancer. The trial combines the rapid-action treatment (IVIG) to induce symptom remission (stop it from returning), with a longer-action therapy (rituximab) to maintain remission. The aim of this study is to examine if immunotherapy is an effective treatment for antibody-associated psychosis, either in first episode psychosis (FEP) or relapse following remission, alongside antipsychotic medication if required.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31174586 protocol (added 10/06/2019)
You can take part if:
You may not be able to take part if:
1. Duration of current episode of psychosis greater than 24 months2. Alternative co-existing severe neurological disease, including tumour, hippocampal sclerosis with refractory epilepsy, probable dementia with evidence of atrophy on brain imaging, moderate or severe learning disability3. Any evidence of a current acute encephalopathy (for instance coma, seizures)4. Hepatitis B, Hepatitis C or HIV positivity; severe hypogammaglobulinaemia5. Previous malignancy (to be usually excluded unless agreed with CI)6. Pregnant, breast feeding or inadequate contraception if female7. Hypersensitivity or absolute contra-indication to any study medication, murine proteins or excipients8. Live vaccine within last three months9. Previous treatment with rituximab in the past 12 months10. Severe infection and severe heart failure11. Any other medical illness or disability that, in the opinion of the investigator, would compromise effective study participation12. Concurrent enrolment in other CTIMPs
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mr
Francis
Dowling
-
francis.dowling@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and funded by Medical Research Council.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 32531
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
